ANTX | AN2 Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.2350 - 1.2799
52 Week Range	0.8700 - 22.22
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	105,268
Average Volume	492,520
Shares Outstanding	29,878,890
Market Cap	37,647,401
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-03-25

Valuation
Profitability
Growth
Health
P/E Ratio	-0.63
Forward P/E Ratio	N/A
EPS	-1.99
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	41
Country	USA
Website	ANTX

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

ANTX's peers: AADI, ACIU, ACXP, ADAG, ADMA, ADVM, AVTE, ACRV, RZLT, ANEB, MLYS, MOLN, PHVS, PEPG, PMVP, ELYM, MNOV, ALVR, ANIX, ATHE, ATXS, AURA, BCAB, BCDA, BCLI, BNOX, PMCB, CADL, PTIX, CDXC, CELC, CING, CRBP, CSBR, DYAI, EQ, GLYC, GNFT, GNTA, IKT, IMNM, INMB, JANX, LVTX, MBRX, MGNX, MNPR, OLMA, OPT, ORIC, PCSA, PRAX, PRLD, PSTX, RAPT, RGNX, RLYB, SEER, SLGL, SYBX, TRVI, XLO, BLTE, AREN, QNCX, LSTA, VANI, ZVRA, CVKD

*Chart delayed

Analyzing fundamentals for ANTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ANTX Fundamentals page.

Watching at ANTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ANTX Technicals page.